Dr. Vishnukamal Golla, spoke about the need to better connect care and how Evolent is taking on the challenge in a recent episode of Healthcare Finance Management Association’s Voices podcast.
This podcast originally published on the HFMA website. To listen to the entire episode on HFMA’s site click here: https://www.hfma.org/cost-effectiveness-of-health/clinical-outcomes-improvement/the-dystopian-state-of-primary-care/
Could generative AI replace expert consensus for devising clinical guidelines? Our chief medical officer takes a look.
To reduce the fragmentation of care for complex conditions, we need to take on the fee-for-service models that contribute to it, says Evolent’s Dr. Vishnukamal Golla.
Cancer treatment and the time spent traveling for care are often very time-consuming. By recognizing and working to decrease time toxicity for patients with cancer, we can lessen their burden.
A stronger, unified voice in our scientific community will impact the accessibility of genetic testing so that it becomes standard preventive care for everyone who qualifies — and who wants it.
Addition will help Evolent to increase first-pass approvals and streamline data collection in complex medical decision making.
Joint offering will seek to to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S.
Dr. Matthew Walker writes in STAT about one big step to make peer conversations more collegial and productive.
2:03Our evidence-driven, patient-first model helps produce more informed decisions.
Company's solutions are coming together to improve outcomes for people living with complex health conditions.
Our CMO, Dr. Andrew Hertler, talks to Yahoo Life about identifying which patients need genetic testing or aggressive cancer screening, the issues surrounding prophylactic surgery, and more.
Becker's highlights our CMO's predictions on the future of health care.
Dr. Andrew Hertler discussed the importance of prophylactic mastectomy for individuals carrying BRCA1, BRCA2 and other deleterious mutations.
Our vice president of pharmacy explores the hard-to-predict impacts of drug price negotiations on consumers, plans and pharmaceutical companies.
Our CMO speaks with Urban Health Today about who should get screened, the role of primary care physicians in identifying at-risk individuals, and more.
Two Evolent experts discuss the benefits of genetic testing in oncology in American Journal of Managed Care.
Evolent takes a multifaceted approach to help providers navigate shortages of cisplatin, carboplatin and other anti-cancer drugs.
Our chief strategy officer speaks with Becker's about the largely untapped potential of value-based specialty care.
Oncology Care Partners CEO Erich Mounce describes how his practices are purpose-built for value.
Evolent is leveraging our expertise in two key specialties to reduce cardiovascular damage related to cancer drugs.
An Evolent program reduces unnecessary radiation treatments for breast cancer without compromising efficacy.